Burning Rock Biotech Limited Sponsored ADR

BNR Healthcare Diagnostics & Research

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

12.69 2.91 −18.65%
Market cap
$137.1M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.95
Beneish M
−2.47
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(19.18%) (10.14%) (11.17%) (13.08%)
Piotroski F-Score
6 6 6 5
ROA
(12.79%) (6.64%) (7.40%) (8.81%)
ROIC
(75.01%) (61.14%) (37.52%) (50.66%)
Return on Tangible Assets
(21.52%) (10.59%) (11.89%) (14.11%)
Average Days of Receivables
127.63 114.74 116.89 126.29
Free Cash Flow per Share
(0.37) (1.52) (0.05) (0.02)
Free Cash Flow
(4.01) (16.19) (5.07) (2.21)
Other line items

Show all line items

Columns are period end dates